These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20103604)

  • 1. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.
    Bhide RS; Lombardo LJ; Hunt JT; Cai ZW; Barrish JC; Galbraith S; Jeyaseelan R; Mortillo S; Wautlet BS; Krishnan B; Kukral D; Malone H; Lewin AC; Henley BJ; Fargnoli J
    Mol Cancer Ther; 2010 Feb; 9(2):369-78. PubMed ID: 20103604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist.
    Ayers M; Fargnoli J; Lewin A; Wu Q; Platero JS
    Cancer Res; 2007 Jul; 67(14):6899-906. PubMed ID: 17638901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.
    Patel RR; Sengupta S; Kim HR; Klein-Szanto AJ; Pyle JR; Zhu F; Li T; Ross EA; Oseni S; Fargnoli J; Jordan VC
    Eur J Cancer; 2010 Jun; 46(9):1537-53. PubMed ID: 20303261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
    Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
    Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats.
    Lin HC; Huang YT; Yang YY; Lee PC; Hwang LH; Lee WP; Kuo YJ; Lee KC; Hsieh YC; Liu RS
    J Gastroenterol Hepatol; 2014 May; 29(5):1073-82. PubMed ID: 24325631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.
    Gong J; Gan J; Masson E; Syed S; Xia YQ; Williams D; Pursley J; Jemal M; Humphreys WG; Iyer RA
    Drug Metab Dispos; 2012 Dec; 40(12):2374-80. PubMed ID: 22983304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.
    Syed S; Clemens PL; Lathers D; Kollia G; Dhar A; Walters I; Masson E
    J Clin Pharmacol; 2012 Jun; 52(6):914-21. PubMed ID: 21659627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
    Allen E; Walters IB; Hanahan D
    Clin Cancer Res; 2011 Aug; 17(16):5299-310. PubMed ID: 21622725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.
    Shiang CY; Qi Y; Wang B; Lazar V; Wang J; Fraser Symmans W; Hortobagyi GN; Andre F; Pusztai L
    Breast Cancer Res Treat; 2010 Oct; 123(3):747-55. PubMed ID: 20024612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brivanib alaninate for cancer.
    Diaz-Padilla I; Siu LL
    Expert Opin Investig Drugs; 2011 Apr; 20(4):577-86. PubMed ID: 21391890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
    Gong J; Gan J; Caceres-Cortes J; Christopher LJ; Arora V; Masson E; Williams D; Pursley J; Allentoff A; Lago M; Tran SB; Iyer RA
    Drug Metab Dispos; 2011 May; 39(5):891-903. PubMed ID: 21289073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.
    Dempke WC; Zippel R
    Anticancer Res; 2010 Nov; 30(11):4477-83. PubMed ID: 21115896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
    Jonker DJ; Rosen LS; Sawyer MB; de Braud F; Wilding G; Sweeney CJ; Jayson GC; McArthur GA; Rustin G; Goss G; Kantor J; Velasquez L; Syed S; Mokliatchouk O; Feltquate DM; Kollia G; Nuyten DSA; Galbraith S
    Ann Oncol; 2011 Jun; 22(6):1413-1419. PubMed ID: 21131369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
    El-Khoueiry A; Posey JA; Castillo Ferrando JR; Krishnamurthi SS; Syed S; Kollia G; Walters I; Fischer BS; Masson E
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):53-64. PubMed ID: 23719718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).
    Cai ZW; Zhang Y; Borzilleri RM; Qian L; Barbosa S; Wei D; Zheng X; Wu L; Fan J; Shi Z; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Kamath A; Marathe P; D'Arienzo C; Derbin G; Barrish JC; Robl JA; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
    J Med Chem; 2008 Mar; 51(6):1976-80. PubMed ID: 18288793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brivanib alaninate inhibited dengue virus proliferation through VEGFR2/AMPK pathway.
    Wan Y; Wu W; Wan Y; Li L; Zhang J; Chen X; Liu S; Yao X
    Pharmacol Res; 2021 Aug; 170():105721. PubMed ID: 34116207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
    Borzilleri RM; Zheng X; Qian L; Ellis C; Cai ZW; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Fura A; Kamath A; Vyas V; Tokarski JS; Barrish JC; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
    J Med Chem; 2005 Jun; 48(12):3991-4008. PubMed ID: 15943473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.
    Wong TW; Lee FY; Emanuel S; Fairchild C; Fargnoli J; Fink B; Gavai A; Hammell A; Henley B; Hilt C; Hunt JT; Krishnan B; Kukral D; Lewin A; Malone H; Norris D; Oppenheimer S; Vite G; Yu C
    Clin Cancer Res; 2011 Jun; 17(12):4031-41. PubMed ID: 21531814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.